<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02709382</url>
  </required_header>
  <id_info>
    <org_study_id>W-4282-104</org_study_id>
    <nct_id>NCT02709382</nct_id>
  </id_info>
  <brief_title>A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open label, single-dose, pharmacokinetic study to be conducted in male and
      female subjects with normal and impaired renal function. The study will be composed of five
      groups of patients with mild (6 patients), moderate (6 patients), severe (6 patients) renal
      impairment, end stage renal disease patients on hemodialysis (6 patients) and their
      respective matched controls in 1:1 ratio (24 healthy subjects with normal renal function).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma concentrations (Cmax)</measure>
    <time_frame>48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax The elimination half-life (t1/2),</measure>
    <time_frame>48 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>FEP-TAZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefepime and Tazobactam combination; IV infusion over a period of 90 minutes Healthy subjects, Mild and Moderate RI: 4 g (2 g FEP and 2 g TAZ) Severe RI and patients on HD: 2 g (1 g FEP and 1 g TAZ)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefepime and Tazobactam combination</intervention_name>
    <arm_group_label>FEP-TAZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients with renal impairment: mild, moderate, severe and patients on hemodialysis) that
        has been stable OR

          -  Healthy Subjects:

          -  Have normal renal function

          -  No evidence of any disease or condition that may affect pharmacokinetics of FEP-TAZ.

        Exclusion Criteria:

          -  Evidence of hepatorenal or nephritic syndrome

          -  Any clinically significant abnormal findings on medical history, physical
             examination,or clinical laboratory tests (other than those associated with controlled
             diabetes,hypertension, hypercholesterolemia, dyslipidemia, or renal impairment or
             related or causative diseases)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Miami,Division of Clinical Pharmacology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>March 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

